Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Corporate Update (July 2021)

17 slides from Aerie Pharmaceuticals's corporate update, Jul 20, 2021

  1. Slide 1: Approaches to Europe: Strategies for Development and Differentiation

    Slide 1: Approaches to Europe: Strategies for Development and Differentiation

    Approaches to Europe: Strategies for Development and Differentiation David A. Hollander, MD, MBA Chief R&D Officer July 20, 2021 Exhibit 99.1

  2. Slide 2: Important Information

    Slide 2: Important Information

    Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety

  3. Slide 3: Aerie Overview

    Slide 3: Aerie Overview

    Aerie Overview Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA and EMA. AR-15512, AR-1105, AR-13503, AR-14034, and AR-6121 are development stage product candidates and are not approved by any regulatory agency. Aerie IOP–Lowering Products (IP 2030+) Ke

  4. Slide 4: Expanding Aerie Franchise in Europe

    Slide 4: Expanding Aerie Franchise in Europe

    Expanding Aerie Franchise in Europe Marketing Authorisations: Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019 and for Roclanda® (Rocklatan®) in January 2021 Ireland plant approved for U.S. production of Rhopressa® and Rocklatan® Sources: IQVIA Midas data at ex-manufactur

  5. Slide 5: Expanding Aerie Franchise in Europe: Trials vs. Active Comparators

    Slide 5: Expanding Aerie Franchise in Europe: Trials vs. Active Comparators

    Expanding Aerie Franchise in Europe: Trials vs. Active Comparators Mercury 3 Trial: A 90-day efficacy and 6-month safety trial was conducted to demonstrate non-inferiority of Roclanda® (Rocklatan®) to a fixed-dose combination product in Europe (Ganfort®). 70 sites across 11 countries Roclanda demons

  6. Slide 6: Dry Eye: Unmet Need for a Novel MOA that Addresses Symptoms and Signs of Dry Eye

    Slide 6: Dry Eye: Unmet Need for a Novel MOA that Addresses Symptoms and Signs of Dry Eye

    Dry Eye: Unmet Need for a Novel MOA that Addresses Symptoms and Signs of Dry Eye Pharmaceutical treatments approved today in US and Europe for chronic dry eye are anti-inflammatories, which are often associated with poor compliance secondary to delayed onset or poor tolerability. US: Ciclosporine 0.

  7. Slide 7: TRPM8 receptors and AR-15512 mechanism in tear film homeostasis

    Slide 7: TRPM8 receptors and AR-15512 mechanism in tear film homeostasis

    TRPM8 (transient receptor potential melastatin) receptors are cold-sensitive thermoreceptors that play key role in tear film homeostasis.1-2 Located on eyelid and cornea TRPM8 channels detect drops in corneal temperature associated with tear evaporation on ocular surface Modulate basal tear secretio

  8. Slide 8: AR-15512 (AVX-012): Phase 2a Results

    Slide 8: AR-15512 (AVX-012): Phase 2a Results

    AR-15512 (AVX-012): Phase 2a Results h Symptoms: SANDE Score Percentage of patients improving ≥20 score Primary Endpoint: % of subjects achieving > 20 improvement in SANDE questionnaire Continued improvement in symptoms and signs observed at each visit over 28 days. Statistical significance (p=0.021

  9. Slide 9: AR-15512: Phase 2b COMET-1

    Slide 9: AR-15512: Phase 2b COMET-1

    AR-15512: Phase 2b COMET-1 COMET-1 “Cold-Thermoreceptor Modulation as an Effective Treatment for DED” Objective: To evaluate the safety, tolerability and efficacy of 2 doses (0.0014% and 0.003%) of topical ophthalmic AR-15512 compared to vehicle administered twice daily in subjects with DED Design:

  10. Slide 10: Aerie's Proprietary Drug Delivery Platform for Retinal Disease

    Slide 10: Aerie's Proprietary Drug Delivery Platform for Retinal Disease

    Aerie’s Proprietary Drug Delivery Platform for Retinal Disease – Predictable and Flexible Customizable drug elution, reproducible manufacturing Proprietary bio-erodible formulations, PRINT ® manufacturing Longer treatment duration, reduced injection frequency Enables once or twice per year IVT injec

  11. Slide 11: AR-1105 Dexamethasone Intravitreal Implant

    Slide 11: AR-1105 Dexamethasone Intravitreal Implant

    AR-1105 Dexamethasone Intravitreal Implant Despite advances in treatments for retinal diseases (RVO, DME), there remains an unmet need for a sustained release intravitreal corticosteroid that lasts at least 6 months and offers a favorable safety profile. AR-1105 Dexamethasone Intravitreal Implant (3

  12. Slide 12: AR-1105 Sustained Release Steroid Opportunity

    Slide 12: AR-1105 Sustained Release Steroid Opportunity

    AR-1105 Sustained Release Steroid Opportunity Prevalence of diabetes mellitus increasing and DME market is growing worldwide.1 The 6-month sustained efficacy of AR-1105 in the Ph 2 study may render this product, if approved, highly competitive in both the U.S. and European markets AR-1105 may be vie

  13. Slide 13: AR-14034 SR (Axitinib) Implant: Market Opportunity

    Slide 13: AR-14034 SR (Axitinib) Implant: Market Opportunity

    AR-14034 SR (Axitinib) Implant: Market Opportunity 1. Market Scope Estimates 2020; http://market-scope.com/ Aflibercept Ranibizumab Bevacizumab Brolucizumab Axitinib 2019 IVT anti-VEGF worldwide market $13B; est. $22B by 2025.1 Current anti-VEGF pipeline dominated by longer duration products targeti

  14. Slide 14: AR-14034 SR (Axitinib) Implant: Preferred Small Molecule for VEGF Inhibition

    Slide 14: AR-14034 SR (Axitinib) Implant: Preferred Small Molecule for VEGF Inhibition

    AR-14034 SR (Axitinib) Implant: Preferred Small Molecule for VEGF Inhibition Axitinib Pan-VEGF receptor inhibitor (inhibits all isoforms of VEGF-R) Approved for systemic use for treatment of renal cell carcinoma (2012) Higher potency and less off-target activity than other small molecule inhibitors.

  15. Slide 15: Unmet need for an effective and safe topical ophthalmic steroid (AR-6121)

    Slide 15: Unmet need for an effective and safe topical ophthalmic steroid (AR-6121)

    There remains unmet need for an effective and safe topical ophthalmic steroid. All topical steroids have side effects, including increases in IOP and cataract formation correlated with potency, duration of use, and patient risk factors. There are ~ 11 million steroid TRx units in US market alone.1 A

  16. Slide 16: Aerie Globalization

    Slide 16: Aerie Globalization

    Aerie Globalization Aerie continues to drive Rhopressa® and Rocklatan® volume growth in the U.S. Ireland manufacturing facility approved for U.S. production of Rhopressa® and Rocklatan® Globalization plan underway with glaucoma franchise approved in Europe. Preparing pricing discussions in Europe wi

  17. Slide 17: Thank you

    Slide 17: Thank you

    Thank you gene

Source: SEC EDGAR · 8-K filed Jul 20, 2021

More decks from Aerie Pharmaceuticals Inc.